In 2000 a randomised crossover study in Biochemical Pharmacology went looking for cytidine in human plasma after oral citicoline and could not find it. Across all three oral amounts tested in twelve fasting subjects, plasma cytidine stayed below twice the assay blank, under 100 nanomolar. What rose instead was uridine, by 70 to 90 percent at the lowest amount, together with a rise in plasma choline that tracked how much had been given.
That is the sharpest documented difference between alpha-GPC and citicoline metabolism, and it is a difference between species as much as between molecules. The authors concluded that the circulating substrates through which oral citicoline reaches membrane phosphatide synthesis in the human brain are uridine and choline — not cytidine and choline, as in rats. Tracking that conversion in a laboratory starts from a citicoline analytical reference standard of documented identity, so that the parent compound can be told apart from its uridine and choline products.
What Is the Difference Between Alpha-GPC and Citicoline Metabolism
Both compounds are described in the literature as cholinergic precursors, and both deliver choline. They arrive by different chemistry.
Citicoline is cytidine 5-prime-diphosphocholine, a nucleotide conjugate. Reviews of its pharmacology state that absorption by the oral route is virtually complete, that oral bioavailability is therefore close to intravenous, and that the molecule releases its two components, cytidine and choline, after hydrolysis. A 2015 review adds where that hydrolysis happens: in the gut wall and in the liver. The intact dinucleotide is not what circulates.
Alpha-GPC, systematically L-alpha-glycerylphosphorylcholine and known in pharmacopoeial usage as choline alfoscerate, is a phosphodiester of choline and glycerol. It carries no nucleoside at all. A 2025 review in the Journal of Food Science puts its choline content at 41 percent by weight and notes that the compound occurs in nature predominantly in the L configuration.
So the two molecules share one hydrolysis product and nothing else. Citicoline additionally supplies a pyrimidine; alpha-GPC additionally supplies a glycerophosphate backbone.
Where Glycerophosphocholine Comes From Inside a Cell
Alpha-GPC is not an exotic molecule from the point of view of a cell. It is a normal intermediate in the breakdown of phosphatidylcholine.
Work published in Biochimica et Biophysica Acta in 1989, on mouse neuroblastoma, rat glioma, primary rat brain glia and human fibroblasts, traced the principal degradation route as phosphatidylcholine to lysophosphatidylcholine to glycerophosphocholine to glycerophosphate plus choline. Glycerophosphocholine was the first quantitatively major degradation product in that sequence. It can be generated by phospholipase A1 or A2 followed by a lysophospholipase, or by a phospholipase B releasing both fatty acids in one coordinated attack.
The same study showed that the two lysophosphatidylcholine isomers are handled differently: the 2-acyl species was reacylated back to phosphatidylcholine faster than the 1-acyl species in both cell lines, while hydrolysis onward to glycerophosphocholine ran higher with the 1-acyl species. Only the 1-acyl form accumulated.
The CDP-Choline Cycle That Both Molecules Feed
Downstream, the two converge. The CDP-choline pathway of phosphatidylcholine biosynthesis, first described more than fifty years ago, is reviewed in Biochimica et Biophysica Acta as a cycle of synthesis and degradation rather than a one way route. Its mammalian components are choline transport, choline kinase, phosphocholine cytidylyltransferase and choline phosphotransferase, and the regulation of each enzyme isoform is cell and tissue specific.
Two consequences follow for anything called a precursor. Free choline enters at the top of the cycle, through choline kinase. Cytidine or uridine enters the same cycle at the nucleotide step, because cytidine triphosphate is the cosubstrate for phosphocholine cytidylyltransferase. Supplying one of the two is not equivalent to supplying both, and the review notes that regulated phosphatidylcholine turnover, mediated by phospholipases or by neuropathy target esterase, is itself part of the cycle.
| Property | Alpha-GPC | Citicoline |
|---|---|---|
| PubChem compound identifier | 657272 | 13804 |
| Registry number | 28319-77-9 | 987-78-0 |
| Molecular formula | C8H20NO6P | C14H26N4O11P2 |
| Molecular weight | 257.22 g/mol | 488.32 g/mol |
| Hydrolysis products cited | Glycerophosphate plus choline | Cytidine plus choline |
What the Radiolabel Experiments Measured in Animals
The claim that a precursor reaches acetylcholine needs a tracer, not an inference. A 1992 study in the European Journal of Pharmacology provided one: intravenous carbon-14 labelled alpha-GPC in rats produced carbon-14 labelled acetylcholine. The same work used hippocampal microdialysis to record acetylcholine release in vivo and measured synthesis in tissue slices, finding release that rose with the amount administered up to a plateau.
That study also ran a scopolamine model of induced amnesia in a passive avoidance task, and reported reversal of the impairment. It is a rodent pharmacology result on a muscarinic blockade model, which is a narrower statement than it is often made to carry. Material for tracer work of this kind has to be characterised first, which is why radiolabel and microdialysis protocols are run against an alpha-GPC analytical reference standard of documented identity and stereochemistry rather than against unspecified material.
What Large Human Datasets Reported, Including the Disagreements
The human literature on citicoline contains one large negative trial. ICTUS, published in The Lancet in 2012, randomised 2298 patients with moderate to severe acute ischaemic stroke at 37 centres in Spain, 11 in Portugal and 11 in Germany. The trial was stopped for futility at the third interim analysis. Global recovery at 90 days was similar in both arms, with an odds ratio of 1.03 and a confidence interval spanning unity, and no significant differences in safety variables. The published conclusion was that under the circumstances of that trial citicoline was not efficacious in that indication.
The alpha-GPC record is observational and internally contradictory. A cohort study in JAMA Network Open in 2021, drawn from South Korea’s National Health Insurance Service and covering more than twelve million individuals aged 50 or over, compared those with prescription records for alpha-GPC against matched controls. The matched analysis reported an adjusted hazard ratio of 1.43 for total stroke, 1.34 for ischaemic stroke and 1.37 for haemorrhagic stroke, with risk rising as prescribed duration increased. The authors raised trimethylamine-N-oxide, a microbial metabolite of choline, as a candidate mechanism and called for work to test it.
A 2025 cohort in The Journal of Prevention of Alzheimer’s Disease, drawn from the same national database but restricted to 508 107 patients newly diagnosed with mild cognitive impairment, reported hazard ratios below one for conversion to Alzheimer’s disease dementia and to vascular dementia, and a decrease in stroke risk confined to patients who did not convert. Two analyses of one insurance database, different populations and periods, opposite directions on stroke. Neither design can establish causation, and the disagreement is the finding.
Why the Literature Contains No Direct Comparison
A 2013 review in Clinical Chemistry and Laboratory Medicine sets out the historical context: precursor loading with choline or lecithin was tried first in disorders marked by cholinergic decline, and was discontinued after negative clinical results. That the earlier attempts failed does not transfer to later molecules, and the review is explicit that the negative results obtained with choline and lecithin cannot be generalised across the whole class.
What does not exist, in the sources read for this article, is a controlled head to head study of alpha-GPC against citicoline on a shared endpoint in the same subjects. The two have been examined in separate populations, separate indications and separate decades. Comparisons between them are therefore comparisons between literatures, not between arms of a trial, and this article does not rank them. The 2015 citicoline review is candid about the same problem from its own side, noting that some studies found no evidence of efficacy and that large trials were still needed.
Frequently asked questions
What does citicoline break down into in humans?
Into choline and a pyrimidine nucleoside. Pharmacological reviews describe hydrolysis in the gut wall and liver releasing cytidine and choline. Measured in human plasma, however, cytidine stayed below 100 nanomolar while uridine rose substantially, so the circulating pair reaching the brain appears to be uridine and choline.
Does oral citicoline raise plasma cytidine or uridine?
Uridine, in the one human study that measured both. Plasma uridine was significantly elevated for five to six hours after every amount tested, rising 70 to 90 percent at the lowest and 100 to 120 percent at the middle amount, with no further increase beyond that. Plasma cytidine was not reliably detectable.
How much choline is in alpha-GPC by weight?
A 2025 review in the Journal of Food Science states 41 percent by weight, and attributes the compound’s interest as a choline source to that figure combined with its ability to cross the blood-brain barrier. The molecule is a phosphodiester of choline and glycerol, occurring in nature predominantly in the L configuration.
Where does glycerophosphocholine come from inside cells?
From phosphatidylcholine breakdown. Cell culture work traced the principal route as phosphatidylcholine to lysophosphatidylcholine to glycerophosphocholine to glycerophosphate plus choline, with glycerophosphocholine the first quantitatively major degradation product. It can form through phospholipase A1 or A2 followed by a lysophospholipase, or through phospholipase B.
Was alpha-GPC linked to stroke risk in cohort studies?
In one, yes. A 2021 analysis of South Korean national insurance data reported an adjusted hazard ratio of 1.43 for total stroke in matched comparison, rising with prescribed duration. A 2025 cohort from the same database, restricted to mild cognitive impairment, reported the opposite direction. Both are observational and neither establishes causation.
What did the ICTUS trial find about citicoline in stroke?
No benefit on its primary outcome. The trial randomised 2298 patients with moderate to severe acute ischaemic stroke and was halted for futility at the third interim analysis. Global recovery at 90 days gave an odds ratio of 1.03 with a confidence interval crossing one, and safety variables did not differ between arms.
Is there a head to head trial of alpha-GPC and citicoline?
None was found in the sources read for this article. The two compounds have been studied in different populations, indications and decades, so any comparison between them is a comparison between separate literatures rather than between randomised arms. That limitation applies to every summary that places them side by side.
References
- Wurtman, Regan, Ulus, Yu, Biochemical Pharmacology, 2000 — effect of oral CDP-choline on plasma choline and uridine levels in humans
- Fagone and Jackowski, Biochimica et Biophysica Acta, 2013 — phosphatidylcholine and the CDP-choline cycle
- Morash, Cook, Spence, Biochimica et Biophysica Acta, 1989 — lysophosphatidylcholine as an intermediate in glycerophosphocholine synthesis
- Sigala, Imperato, Rizzonelli et al., European Journal of Pharmacology, 1992 — L-alpha-glycerylphosphorylcholine and hippocampal cholinergic transmission in the rat
- Davalos, Alvarez-Sabin, Castillo et al., The Lancet, 2012 — citicoline in the treatment of acute ischaemic stroke, the ICTUS trial
- Lee, Choi, Chang et al., JAMA Network Open, 2021 — association of L-alpha glycerylphosphorylcholine with subsequent stroke risk after 10 years
- Kim, Park, Kim et al., Journal of Prevention of Alzheimer’s Disease, 2025 — L-alpha glycerylphosphorylcholine and delayed dementia conversion in South Korea
- Gareri, Castagna, Cotroneo et al., Clinical Interventions in Aging, 2015 — the role of citicoline in cognitive impairment
- Tayebati and Amenta, Clinical Chemistry and Laboratory Medicine, 2013 — choline-containing phospholipids and brain functional pathways
- Li, Zhang, Wang et al., Journal of Food Science, 2025 — L-alpha-glycerylphosphorylcholine: preparation techniques and biological effects
- Secades and Lorenzo, Methods and Findings in Experimental and Clinical Pharmacology, 2006 — citicoline: pharmacological and clinical review, 2006 update
Research use only. Nonsensia supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.
Filed under: Nootropics Research
This article is part of our guide to The Evidence Base for Cognition Research Compounds: A Critical Guide.
The compound discussed in this article is available as an analytical reference standard: Alpha-GPC (Choline Alfoscerate) ≥99% – Analytical Reference Standard | CAS 28319-77-9.